Royalty Pharma plc Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2018 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Royalty Pharma plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2018 to 2023.
- Royalty Pharma plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending December 31, 2023 was $494M.
- Royalty Pharma plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending December 31, 2023 was $1.13B, a 4401% increase year-over-year.
- Royalty Pharma plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $1.13B, a 4401% increase from 2022.
- Royalty Pharma plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $25.2M, a 95.8% decline from 2021.
- Royalty Pharma plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was $598M, a 41.9% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)